| First Author | Dacheux MA | Year | 2024 |
| Journal | iScience | Volume | 27 |
| Issue | 10 | Pages | 110971 |
| PubMed ID | 39398245 | Mgi Jnum | J:358319 |
| Mgi Id | MGI:7749737 | Doi | 10.1016/j.isci.2024.110971 |
| Citation | Dacheux MA, et al. (2024) Deleting autotaxin in LysM+ myeloid cells impairs innate tumor immunity in models of metastatic melanoma. iScience 27(10):110971 |
| abstractText | Autotaxin (ATX) is a lysophospholipase D that generates lysophosphatidic acid (LPA) and regulates cancer metastasis, therapeutic resistance, and tumor immunity. We found that myeloid cells in human melanoma biopsies abundantly express ATX and investigated its role in modulating innate tumor immunity using two models of melanoma metastasis-spontaneous and experimental. Targeted knockout of ATX in LysM+ myeloid cells in mice (LysM-KO) reduced both spontaneous and experimental B16-F10 melanoma metastases by >/= 50%. Immunoprofiling revealed differences in M2-like alveolar macrophages, neutrophils and regulatory T cells in the metastatic lungs of LysM-WT versus LysM-KO that are model-dependent. These differences extend systemically, with LysM-KO mice bearing experimental metastasis having fewer neutrophils in the spleen than LysM-WT mice. Our results show that (1) LysM+ myeloid cells are an important source of ATX/LPA that promote melanoma metastasis by altering innate tumor immunity, and (2) intratumor and systemic immune profiles vary dynamically during disease progression and are model-dependent. |
